## Table of contents

[comment]: <> Table of contents is generated automatically

## General questions

### How should I cite or acknowledge this work?

Please do cite and link back to CoVariants.org if you use this resource! 

If you use screenshots from CoVariants.org, please do ensure a you credit the website and provide a link back to CoVariants.org.

TODO:

- add citation
- add linking info
- add social media sharing info and links

Citation:

```
Emma B. Hodcroft. 2021. "CoVariants: SARS-CoV-2 Mutations and Variants of Interest." www.covariants.org
```

Emma Hodcroft, PhD, is a researcher at the Institute of Social and Preventive Medicine, University of Bern in Bern, Switzerland.

### How can I use this work?

TODO:

- Describe permitted usage, content, data and software licensing

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce eget facilisis ipsum. Praesent lobortis et quam ac tempor. Nam elementum nulla eleifend auctor feugiat. Morbi nisl purus, congue nec sapien quis, rhoncus elementum felis. Duis volutpat, velit sed scelerisque accumsan, sem sapien auctor erat, non faucibus ligula lectus nec eros. Curabitur sed elementum nisl. Vestibulum venenatis in justo at rutrum. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Morbi rhoncus, mauris vel egestas dapibus, diam lectus vulputate purus, vitae dictum erat leo eu lectus. Ut id dapibus augue, eget hendrerit felis. Etiam vitae feugiat tellus. Vestibulum a tincidunt libero, dictum facilisis purus.

Vivamus nec enim turpis. Praesent semper nibh non varius malesuada. Quisque at elementum arcu, sed maximus erat. Etiam facilisis ipsum non imperdiet pretium. Pellentesque sed nisl non enim dictum tempus. Duis pharetra massa sed lorem dapibus fringilla. Pellentesque dignissim, dui et mollis laoreet, orci neque malesuada ante, ac lacinia eros ex lobortis libero. Duis lobortis purus eget leo faucibus ullamcorper. Etiam at euismod enim. Ut vitae ullamcorper leo, id fermentum odio.

Proin arcu ex, tincidunt eu condimentum ac, dignissim et elit. Suspendisse potenti. In varius auctor augue, non convallis risus vehicula vitae. Fusce in blandit diam. Fusce at tortor felis. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Sed molestie in risus nec condimentum. Ut nisl dui, consectetur sit amet magna et, elementum sagittis leo. Fusce ipsum eros, fermentum non eleifend non, commodo sit amet ante.

### How can I contribute to this work (add a paper, fix an error, or make a suggestion)?

**I welcome PR requests to this repository providing new links and information!** The more detail you can include in a [pull request (PR)](https://github.com/hodcroftlab/covariants/pulls) the faster I'll be able to review it!

If possible, provide a PR that adds/edits the appropriate links/etc, and I can merge it faster - if you can't or don't know how to do that, making an [issue](https://github.com/hodcroftlab/covariants/issues) is fine! (But I might be a little slower incorporating it!)

You can also use the "Propose changes to this section" links that you will often see in the top-right of sections across the website.

TODO:

- TODO: Add link to discussion and twitter.

- TODO: Add link to issues and pull requests.

- TODO: Add content contributors guide. Where, how, what. How to add new content and data.

- TODO: Add software developers guide.


### I want to stay up-to-date on the topic. What you suggest?

To stay up-to-date on SARS-CoV-2 variants, you can follow Emma Hodcroft on Twitter ([@firefoxx66](https://twitter.com/firefoxx66)) - she often tweets about updates and changes to the website.

- TODO: suggest following on Twitter
- TODO: suggest additional sources

## Questions about the Variants

### What do the names you use mean?

Variants/mutations are listed by the location of a mutation in the spike protein (`S:`). The letter after `:` indicates the original amino-acid, the number is the position of the amino-acid in the spike protein, and the last letter is the 'new' amino-acid.

For some builds, like `S:N501` and `S:E484`, there is no last letter. This is because the builds track multiple amino-acid changes.

Some variants have different names, like `20A.EU1` and `20A.EU2`. This is because of their prominence - they've been given 'clade' and 'subclade' names. A defining mutation is often listed in parentheses after the name.

### How do you choose what variants to track?

Generally, variants are added due to a few criteria:
- If they seem to account for a significant fraction of sequences in a region or a country
- If they have expanded quickly in a region or country
- If they are considered a variant of concern or interest
- If their defining mutations are considered of concern or interest

So far, the focus of this website has primarily been on variants found in Europe, but work is in motion to expand this to be more broad.

### Where can I see all the information & plots in one place?

Check out the links below:

[Overview of all mutation tables & graphs](table_overview.md)

[Overview of all mutation country plots](country_overview.md)

---

## What's next?

- See ["About" page](/about)
- View [clusters](/)
